Cambridge Newswire

Comprehensive Real-Time News Feed for Cambridge, MA.

Results 1 - 20 of 53 for "u:bloomberg.com" in Cambridge, MA

  1. Alnylam Drug May Challenge Sanofi, Regeneron, AmgenRead the original story

    Tuesday | The Washington Post

    The experimental drug belongs to a group of treatments that target a protein, PCSK9, that lets too much bad cholesterol circulate in the blood. The results were presented Sunday at the European Society of Cardiology Congress in London.

    Comment?

  2. Alnylam's New Drug May Be Threat to Sanofi, Regeneron, AmgenRead the original story

    Monday Aug 31 | The Washington Post

    A drug from Alnylam Pharmaceuticals Inc. and Medicines Co. cut bad cholesterol levels among patients in a small trial by about as much as new treatments from Sanofi, Regeneron Pharmaceuticals Inc. and Amgen Inc., with far less frequent dosing.

    Comment?

  3. Here's One Thing Standing Between You and Cheaper GasolineRead the original story

    Friday Aug 28 | The Washington Post

    And there's at least one thing standing in the way of a steeper decline at the pumps: ethanol. While the crude rout dragged gasoline futures down about 60 cents a gallon, ethanol's dropped a mere 15 cents -- making it costlier than gasoline this week for the first time since January.

    Comment?

  4. Biogen, Columbia to Map ALS Disease Genes With Ice Bucket MoneyRead the original story

    Tuesday Aug 18 | The Washington Post

    Biogen Inc. and Columbia University Medical Center will map the genes and clinical traits of 1,500 people with ALS, also known as Lou Gehrig's disease, in an attempt to find a treatment for the devastating neurodegenerative disorder. The effort is being financed in part out of the $115 million the ALS Association raised last year in a viral fundraising campaign that had people dump buckets of ice water over their heads and challenge others to do the same.

    Comment?

  5. Gates, Google Join $120 Million Funding for Genome Editing FirmRead the original story

    Monday Aug 10 | Bloomberg

    Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. Editas Medicine Inc. has raised $120 million from investors to support development of a technology that can precisely edit DNA and potentially treat fatal genetic diseases.

    Comment?

  6. Drug Projected at $1 Million Has Spark Mulling Installment PlanRead the original story

    Thursday Aug 6 | The Washington Post

    Drugmaker Spark Therapeutics Inc. is considering installment payments for a promising gene therapy for blindness that analysts are projecting will come with a hefty price tag. The company is in discussions with health insurers and drug benefits managers about staggered-payment alternatives including pay-for-performance models that would spread costs over an extended period based on effectiveness, Chief Executive Officer Jeff Marrazzo said in an interview.

    Comment?

  7. In Race to Treat Rare Disease, Sarepta Seeks PurchasesRead the original story

    Jul 16, 2015 | The Washington Post

    The two companies are in a race to bring the products to market, and buying a drug could let Sarepta eventually combine therapies into a more effective cocktail. BioMarin submitted its drug to the U.S. Food and Drug Administration in April, beating Cambridge, Massachusetts-based Sarepta by a matter of weeks.

    Comment?

  8. In Race to Treat Muscle-Wasting Disease, Sarepta Seeks PurchasesRead the original story

    Jul 14, 2015 | The Washington Post

    Sarepta Therapeutics Inc. is looking to buy another drug in an escalating battle with bigger rival BioMarin Pharmaceutical Inc. to treat Duchenne muscular dystrophy, the rare and deadly muscle-wasting disease. The two companies are in a race to bring the products to market, and buying a drug could let Sarepta eventually combine therapies into a more effective cocktail.

    Comment?

  9. Education Department Dismisses Harvard Asian-American Discrimination ComplaintRead the original story w/Photo

    Jul 7, 2015 | Bloomberg

    Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. The U.S. Education Department dismissed a complaint against Harvard University alleging discrimination against Asian-American applicants in undergraduate admissions because a similar case is pending in federal court.

    Comment?

  10. Kyushu Electric Edges Closer to Nuclear Restart With RefuelingRead the original story

    Jul 6, 2015 | The Washington Post

    Kyushu Electric Power Co. will begin refueling one of its reactors at its Sendai nuclear plant in southern Japan ahead of a resumption of operations scheduled for August.

    Comment?

  11. Cancer Therapy Boosts Appeal of Juno, Kite as Targets: Real M&ARead the original story

    Jun 23, 2015 | The Washington Post

    Juno Therapeutics Inc., Kite Pharma Inc., Bluebird Bio Inc. and Cellectis SA are among firms working on CAR T, a gene therapy that supercharges the immune system. They may prove enticing to large drugmakers, even if questions persist about whether promising results from small trials can be widely replicated.

    Comment?

  12. Former Sanofi CEO Reinvents Himself With Bertarelli FundRead the original story

    Jun 23, 2015 | The Washington Post

    Viehbacher, the former chief executive of France's largest drugmaker, will run Swiss billionaire Ernesto Bertarelli's U.S. based Gurnet Point Capital fund, according to a statement. He has also joined the board of the technology transfer company PureTech Health Plc, which raised $171 million in an initial public offering on the London Stock Exchange this month.

    Comment?

  13. Former Sanofi CEO Makes Science Comeback With Bertarelli FundRead the original story

    Jun 23, 2015 | The Washington Post

    Viehbacher, the former chief executive at France's largest drugmaker, will run Swiss billionaire Ernesto Bertarelli's U.S. based Gurnet Point Capital fund, according to an e-mailed statement Tuesday. He has also joined the board of the healthcare solutions company PureTech Health Plc, which raised $171 million in an initial public offering on the London Stock Exchange this month.

    Comment?

  14. Chinese Lead Foreign U.S. Home Purchases for First TimeRead the original story

    Jun 17, 2015 | Bloomberg

    Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. Chinese buyers topped Canadians to rank as the biggest foreign purchasers of U.S. homes by both sales and dollar volume, accounting for more than a quarter of all international spending.

    Comment?

  15. Synergy Soars as Drug That May Spur Buyout Beat ExpectationsRead the original story

    Jun 17, 2015 | The Washington Post

    In a trial of 1,346 patients with chronic idiopathic constipation, 21 percent responded to plecanatide at a 3- milligram dose, compared with 10 percent given a placebo, the New York-based company said in a statement on Wednesday. The chief side effect of diarrhea was experienced by 5.9 percent of patients at that dose, a far lower rate than analysts expected.

    Comment?

  16. FDA to Work With Online Patient Forum to Mine Safety DataRead the original story

    Jun 15, 2015 | The Washington Post

    The FDA is tapping into a broad flow of data sent to PatientsLikeMe, an online site with 350,000 members that says it's the largest and most active patient network online. Members often report their drug-use experiences, symptoms and hospitalizations on the site.

    Comment?

  17. FDA to Work With Online Patient Forum to Mine Drug Safety DataRead the original story w/Photo

    Jun 15, 2015 | Bloomberg

    The U.S. Food and Drug Administration is turning to a patient-networking website to get a better handle on the side effects of medications. The FDA is tapping into a broad flow of data sent to PatientsLikeMe , an online site with 350,000 members that says it's the largest and most active patient network online.

    Comment?

  18. Dwyane Wade Goes to HarvardRead the original story w/Photo

    Jun 12, 2015 | The Washington Post

    Dwyane Wade #3 of the Miami Heat looks on during a game against the Sacramento Kings at American Airlines Arena on Feb. 21, 2012 in Miami. LeBron James looks as if he's having a pretty intense time playing in the NBA Finals, but in the meantime, former teammate Dwyane Wade is having a moment of his own.

    Comment?

  19. Scariest U.S. Housing Chart Shows Nasty Scar Years After BustRead the original story

    Jun 11, 2015 | Bloomberg

    A decade after U.S. home sales peaked, 15.4 percent of owners in the first quarter owed more on their mortgages than their properties were worth, according to a report Friday by Zillow Inc. While that's down from a high of 31.4 percent in 2012, it's still alarmingly above the 1 or 2 percent that marks a healthy market, said Humphries, the chief economist at the Seattle-based real-estate data provider. Worse yet: The pace of healing is losing steam.

    Comment?

  20. Roche Takes Another Shot at Alzheimer's After Biogen SuccessRead the original story

    Jun 9, 2015 | The Washington Post

    Roche stopped a trial of gantenerumab in December because patients weren't benefiting more than those receiving a placebo. Four months later, Biogen said that its drug slowed the progression of the disease, supporting a long-held hypothesis that targeting a protein linked to the telltale plaques found in the brains of Alzheimer's patients may yield a treatment.

    Comment?

Cambridge Job Listings
View or post Cambridge job listings on Topix.
Cambridge Real Estate
News, listings, and foreclosures in Cambridge from Topix.
Cambridge Mortgages
Find mortgage rates in Cambridge on Topix.